AI Image
Incyte reports Phase 1 data at ESMO: 81% response rate on pancreatic drug
STAT • • business
Key Points:
- Incyte reported that its targeted drug, combined with chemotherapy, produced lasting tumor responses in some pancreatic cancer patients, supporting its move to late-stage clinical trials.
- Earlier this year, Revolution Medicines received approval for Rasonque, a drug that targets RAS gene mutations and has been shown to extend survival in pancreatic cancer patients.
- Several companies, including Incyte, Revolution Medicines, Verastem, and Hengrui, are developing next-generation drugs aimed at specific RAS gene mutations to improve treatment outcomes.
- These advancements highlight a growing focus on precision medicine targeting RAS mutations, which are common drivers of aggressive pancreatic cancer.
